Nyxoah SA (NYXH) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has shown significant revenue growth in its latest quarter, its financials still reflect substantial losses, and there are no strong positive catalysts or proprietary trading signals to suggest immediate upside potential. The stock's technical indicators are neutral, and analysts have recently lowered their price targets, reflecting cautious sentiment. Given the lack of recent news, options data, or significant trading trends, it is advisable to hold off on buying this stock for now.
The MACD is positive and expanding, indicating a mild bullish momentum. RSI is neutral at 57.257, suggesting no clear overbought or oversold conditions. Moving averages are converging, showing no strong directional trend. Key support is at 2.885, and resistance is at 3.535. Overall, the technical indicators are neutral.
Revenue increased by 346.87% YoY in Q4 2025, indicating strong top-line growth. The stock has a 16.01% chance of gaining in the next month based on historical candlestick patterns.
Net income remains negative at -$23.51M, though it has improved YoY. Gross margin dropped by 12.59% YoY. Analysts have recently lowered price targets, reflecting cautious sentiment. No recent news or significant trading trends from hedge funds or insiders.
In Q4 2025, revenue increased significantly by 346.87% YoY to $5.64M. However, net income remains negative at -$23.51M, though it improved by 37.11% YoY. EPS also improved to -0.59, up 28.26% YoY. Gross margin dropped to 64.23%, down 12.59% YoY, indicating some pressure on profitability.
Analysts have lowered their price targets recently. Stifel reduced the target to $8 from $10 while maintaining a Buy rating, citing reimbursement challenges. Baird lowered the target to $4.62 from $5.87 with a Neutral rating, reflecting cautious optimism as the U.S. rollout progresses. Overall, sentiment is mixed to cautious.